This segment focuses on the research, development, and clinical evaluation of psychedelic-based therapies, particularly for neurological and mental health conditions resulting from traumatic brain injuries. Research and development activities include the formulation of novel drug protocols, preclinical studies, and clinical trials. The company utilizes advanced methodologies in drug discovery and delivery, including exploring various psychedelic compounds and their therapeutic potential. The primary therapeutic area is the treatment of traumatic brain injury (TBI) and associated psychological and neurological symptoms. The patient impact is aimed at improving the quality of life for individuals suffering from TBI, offering potential relief from symptoms such as chronic pain, depression, and cognitive impairment. Wesana Health aims to position itself as a leader in psychedelic medicine, leveraging its intellectual property and partnerships to gain a competitive advantage. Future opportunities include expanding the therapeutic applications of its drug candidates and securing regulatory approvals. This segment involves clinical trials and regulatory compliance, with the goal of obtaining FDA approval for its therapies. Partnerships with research institutions and clinical trial sites are crucial for advancing the development pipeline.